

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments (ID6211)**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No. At consultation, a stakeholder noted that a positive recommendation would not impact people protected by the equality legislation differently to the wider population. But that as with all treatments, the costs incurred by hospital visits and time off work will have a more significant impact on people with lower incomes.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Not relevant.
3. Has any change to the draft scope been agreed to highlight potential equality issues?
Not relevant.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

**Approved by Associate Director (name):** ...Richard Diaz.....

**Date:** 30 May 2024